scholarly journals Secondary Substrate-binding Exosite in the Serine Protease Domain of Activated Protein C Important for Cleavage at Arg-506 but Not at Arg-306 in Factor Va

2001 ◽  
Vol 276 (25) ◽  
pp. 23105-23108 ◽  
Author(s):  
Ute Friedrich ◽  
Gerry A.F. Nicolaes ◽  
Bruno O. Villoutreix ◽  
Björn Dahlbäck
Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 122-122 ◽  
Author(s):  
Amy E. Schmidt ◽  
Pooja Shah ◽  
Emily M. Gauthier ◽  
S. Paul Bajaj

Abstract During physiologic coagulation, the factor VIIa (FVIIa)/tissue factor (TF) complex activates FIX and FX. FVIIa consists of a N-terminal γ-carboxyglutamic acid (Gla) domain, two epidermal growth factor-like (EGF) domains, and a C-terminal serine protease domain. We obtained crystals of FVIIa/soluble TF in the presence of Na+, Rb+, or Choline+ (Ch+) under conditions containing micromolar concentrations of Zn2+. Rb+ is a large monovalent ion and has been used to identify Na+-sites in several proteins; whereas, Ch+ cannot substitute for Na+. The various crystals diffracted from 2.0 to 2.4 Å and belonged to the space group P212121. In the crystal structures, Na+ or Rb+ in FVIIa coordinates to the carbonyl groups of residues 185 (chymotrypsin numbering), 185A, 221, and 224 as well as to two water molecules. Thus, the Na+-site in FVIIa is similar to that of FXa and activated protein C but not to that of thrombin. Ca2+ in the protease domain of FVIIa is coordinated to the carboxylates of Glu70 and Glu80 as seen earlier by Banner and coworkers. Additionally, the crystal structures also showed two Zn2+-sites, one involving His71 and the other involving His117. The Zn2+-sites are unique to FVIIa since the His residues are not present in other proteases. To investigate the role of Na+, Ca2+, and Zn2+-sites in the protease domain of FVIIa, a series of biochemical and kinetic studies were performed. Na+ increased the kcat for hydrolysis of S-2288 (H-D-Ile-Pro-Arg-p-nitroanilide) ~22-fold by FVIIaWT whereas Ca2+ increased it ~by 230-fold. In the presence of Ca2+, Na+ had virtually no effect on the hydrolysis of S-2288; however, in the presence of Na+, Ca2+ increased the kcat ~12-fold. Thus, the increase in kcat by Ca2+ in the presence or absence of Na+ was similar (~250-fold). Further, Na+ had no effect on Km whereas Ca2+ increased it ~3.5-fold. However, the increase by in Km is biologically not pertinent since the Gla and EGF1 domains of FVIIa determine the Km for activation of FIX and FX. Moreover, FVIIaF225P (Na+-site mutant) showed little response to Na+ and FVIIaE80V (Ca2+-site mutant) showed no response to Ca2+ in hydrolyzing S-2288. These data indicate that the Na+ and Ca2+ effects observed are due to the occupancy of the protease domain Na+ and Ca2+ sites. Consistent with the Km data, Na+ had no effect on the binding of p-aminobenzamidine (pAB, S1 site probe) to FVIIaWT. Interestingly, Ca2+ decreased the Ki for pAB binding by ~5-fold indicating that the increase in Km for S-2288 caused by Ca2+ is not related to the S1 site but rather to the S2 and/or S3/S4 sites in FVIIa. In further studies, Zn2+ inhibited the potentiation of S-2288 hydrolysis by FVIIaWT with Ki ~1 of μM in the absence and ~30 μM in the presence of Ca2+. We conclude that the Na+-site in FVIIa is not linked to the synthetic substrate binding site(s), and that the Ca2+-site is linked to the substrate binding site(s). These observations are in contrast to what has been previously observed for FXa and activated protein C. Thus, in the absence of TF, Na+ and Ca2+ are positive regulators for catalysis by FVIIa; whereas, Zn2+ exerts a negative effect. Conceivably, occupancy of the Na+-site and the protease domain Ca2+-site may render FVIIa in a conformation suitable for TF binding and substrate hydrolysis. The local Zn2+ concentration following release by activated platelets at the site of hemostasis could dampen coagulation as a regulatory mechanism.


1999 ◽  
Vol 31 (1) ◽  
pp. 47-51 ◽  
Author(s):  
Kyung Soon Song ◽  
Young Sook Park ◽  
Jong Rak Choi ◽  
Hyun Kyung Kim ◽  
Quehn Park

FEBS Letters ◽  
1995 ◽  
Vol 367 (2) ◽  
pp. 153-157 ◽  
Author(s):  
A. Vincenot ◽  
P. Gaussem ◽  
J.L. Pittet ◽  
S. Debost ◽  
M. Aiach

1997 ◽  
Vol 6 (1) ◽  
pp. 132-140 ◽  
Author(s):  
Andrew J. Gale ◽  
Xi Sun ◽  
Mary J. Heeb ◽  
John H. Griffin

1999 ◽  
Vol 82 (11) ◽  
pp. 1462-1468 ◽  
Author(s):  
José Fernández ◽  
Jari Petäjä ◽  
John Griffin

SummaryUnfractionated heparin potentiates the anticoagulant action of activated protein C (APC) through several mechanisms, including the recently described enhancement of proteolytic inactivation of factor V. Possible anticoagulant synergism between APC and physiologic glycosaminoglycans, pharmacologic low molecular weight heparins (LMWHs), and other heparin derivatives was studied. Dermatan sulfate showed potent APC-enhancing effect. Commercial LMWHs showed differing abilities to promote APC activity, and the molecular weight of LMWHs correlated with enhancement of APC activity. Degree of sulfation of the glycosaminoglycans influenced APC enhancement. However, because dextran sulfates did not potentiate APC action, the presence of sulfate groups per se on a polysaccharide is not sufficient for APC enhancement. As previously for unfractionated heparin, APC anticoagulant activity was enhanced by glycosaminoglycans when factor V but not factor Va was the substrate. Thus, dermatan sulfate and LMWHs exhibit APC enhancing activity in vitro that could be of physiologic and pharmacologic significance.


1992 ◽  
Vol 67 (01) ◽  
pp. 095-100 ◽  
Author(s):  
Paul J Declerck ◽  
Leen Van Keer ◽  
Maria Verstreken ◽  
Désiré Collen

SummaryAn enzyme-linked immunosorbent assay (ELISA) for quantitation of natural and recombinant plasminogen activators containing the serine protease domain (B-chain) of urokinase-type plasminogen activator (u-PA) was developed, based on two murine monoclonal antibodies, MA-4D1E8 and MA-2L3, raised against u-PA and reacting with non-overlapping epitopes in the B-chain. MA-4D1E8 was coated on microtiter plates and bound antigen was quantitated with MA-2L3 conjugated with horseradish peroxidase. The intra-assay, inter-assay and inter-dilution coefficients of variation of the assay were 6%, 15% and 9%, respectively. Using recombinant single-chain u-PA (rscu-PA) as a standard, the u-PA-related antigen level in normal human plasma was 1.4 ± 0.6 ng/ml (mean ± SD, n = 27).The ELISA recognized the following compounds with comparable sensitivity: intact scu-PA (amino acids, AA, 1 to 411), scu-PA-32k (AA 144 to 411), a truncated (thrombin-derived) scu-PA comprising A A 157 to 411, and chimeric t-PA/u-PA molecules including t-PA(AA1-263)/scu-PA(AA144-411), t-PA(AA1-274)/scu-PA(AA138-411) and t-PA(AA87-274)/scu-PA(AA138-411). Conversion of single-chain to two-chain forms of u-PA or inhibition of active two-chain forms with plasminogen activator inhibitor-1 or with the active site serine inhibitor phenyl-methyl-sulfonyl fluoride, did not alter the reactivity in the assay. In contrast, inactivation with α2-antiplasmin or with the active site histidine inhibitor Glu-Gly-Arg-CH2Cl resulted in a 3- to 5-fold reduction of the reactivity. When purified scu-PA-32k was added to pooled normal human plasma at final concentrations ranging from 20 to 1,000 ng/ml, recoveries in the ELISA were between 84 and 110%.The assay was successfully applied for the quantitation of pharmacological levels of scu-PA and t-PA(AA87_274)/scu-PA(AA138-411) in plasma during experimental thrombolysis in baboons.Thus the present ELISA, which is specifically dependent on the presence of the serine protease part of u-PA, is useful for measurement of a wide variety of variants and chimeras of u-PA which are presently being developed for improved thrombolytic therapy.


1992 ◽  
Vol 67 (01) ◽  
pp. 046-049 ◽  
Author(s):  
H A Guglielmone ◽  
M A Vides

SummaryA simple and fast method for the quantitative determination of protein C activity in plasma is here described. The first step consists in the conversion of protein C in the test sample into activated protein C by means of an activator isolated from Southern Copperhead venom. Subsequently, the degradation of factor Va, in presence of protein C-deficient plasma, is measured by the prolongation of the prothrombin time which is proportional to the amount of protein C in the sample. The dose-response curve showed a linear relationship from 6 to 150% protein C activity and the inter- and intra-assay reproducibility was 3.5% and 5.6% respectively. In normal subjects, a mean of protein C level of 98 ± 15% of normal pooled plasma was found. Comparison with the anticoagulant assay in samples of patients with oral anticoagulant, liver cirrhosis, disseminated intravascular coagulation and severe preeclampsia revealed an excellent correlation (r = 0.94, p <0.001). Also, a similar correlation (r = 0.93, p <0.001) existed between amidolytic assay and the method here proposed for all the samples studied without including the oral anticoagulant group. These results allowed us to infer that this method evaluates the ability of protein C to interact with protein S, phospholipids, calcium ions and factor Va.


1982 ◽  
Vol 257 (3) ◽  
pp. 1443-1447
Author(s):  
M.E. Nesheim ◽  
W.M. Canfield ◽  
W. Kisiel ◽  
K.G. Mann

Sign in / Sign up

Export Citation Format

Share Document